Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism

European Journal of Pharmacology

Volumn 420, Issue 1, 2001, Pages 33-43

  Nakamura, Kazuo ^a   Kurasawa, Mitsue ^a  

^a NIPPON ROCHE RESEARCH CENTER   (Japan)

Author keywords

Aniracetam; Anxiety; Conditioned fear stress; Elevated plus maze; Mode of action; Social interaction

Indexed keywords

2 DIBUTYLAMINO 8 HYDROXYTETRALIN; 2 PYRROLIDINONE; 4 AMINOBUTYRIC ACID DERIVATIVE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 5 (PROPARGYLOXYCARBONYL) 1,4,5,6 TETRAHYDROPYRIMIDINE; ANIRACETAM; ANISIC ACID; BROMOCRIPTINE; CDD 0097; DIAZEPAM; DONEPEZIL; DOPAMINE 2 RECEPTOR; DRUG VEHICLE; FLUOXETINE; FLUVOXAMINE MALEATE; HALOPERIDOL; KETANSERIN; LAZABEMIDE; MECAMYLAMINE; METHYLPHENIDATE; MOCLOBEMIDE; MUSCARINIC M1 RECEPTOR AGONIST; N ANISOYL 4 AMINOBUTYRIC ACID; NICOTINE; NICOTINIC RECEPTOR; NORTRIPTYLINE; PHYSOSTIGMINE; PYRIMIDINE DERIVATIVE; SEROTONIN 2A RECEPTOR; TANDOSPIRONE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY NEUROSIS; ARTICLE; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG EFFECT; LOCOMOTION; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; SOCIAL BEHAVIOR; SOCIAL INTERACTION; STRESS; TRANQUILIZING ACTIVITY;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; BROMOCRIPTINE; DIAZEPAM; DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEAR; FLUVOXAMINE; HALOPERIDOL; INDOPHENOL; MALE; MAZE LEARNING; MECAMYLAMINE; MICE; MICE, INBRED ICR; MOCLOBEMIDE; MOTOR ACTIVITY; NICOTINE; NICOTINIC ANTAGONISTS; NORTRIPTYLINE; PHYSOSTIGMINE; PICOLINIC ACIDS; PYRROLIDINONES; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SOCIAL BEHAVIOR; STRESS, PSYCHOLOGICAL;

EID: 0035908077     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(01)01005-6     Document Type: Article

References (58)

1. Aniracetam restores object recognition impaired by age, scopolamine, and nucleus basalis lesions
2. Social behaviour in rats lesioned with ibotenic acid in the hippocampus: Quantitative and qualitative analysis
3. Conditioned fear assessed by freezing and by the suppression of three different baselines
4. Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test
5. Mechanisms of emotional arousal and lasting declarative memory
6. L-Sulpiride, at a low non-neuroleptic dose, prevents conditioned fear stress-induced freezing behavior in rats
7. The neuropsychiatry of stroke
8. Effects of atypical antipsychotic agents on social behavior in rodents
9. Effects in the X-maze anxiety model of agents acting at 5-HT1 and 5-HT2 receptors
10. Models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on memory, psychomotor performance and mood
11. Regional brain function, emotion and disorders of emotion
12. Neurotransmission in the rat amygdala related to fear and anxiety
13. 8-OH-DPAT in the median raphe nucleus decreases while in the medial septal area it may increase anxiety in female rats
14. 2B/2C receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation
15. 2A receptor in dopaminergic neurons in the ventral tegmental area
16. The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs
17. 1A receptor modulation of anxiety in two ethological animal tests
18. 1 receptors
19. Bimodal modulation by nicotine of anxiety in the social interaction test: Role of the dorsal hippocampus
20. 1A and benzodiazepine receptors in the basolateral amygdala modulate anxiety in the social interaction test, but not in the elevated plus-maze
21. Neuroanatomical hypothesis of panic disorder, revised
22. Role of 5-HT in stress, anxiety, and depression
23. Activation of serotonin-immunoreactive cells in the dorsal raphe nucleus in rats exposed to an uncontrollable stressor
24. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: More than 30 years research
25. Risk assessment behaviour: Evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test
26. An electrophysiological characterization of ventral tegmental area dopaminergic neurons during differential pavlovian fear conditioning in the awake rabbit
27. 5-HT drugs in animal models of anxiety
28. 1A receptor agonists in two models of anxiety after dorsal raphe injection
29. 2A receptor: An immunohistochemical demonstration
30. Effect of citalopram, a selective serotonin reuptake inhibitor, on the acquisition of conditioned freezing
31. Serotonergic activation reduces defensive freezing in the conditioned fear paradigm
32. The use of a plus-maze to measure anxiety in the mouse
33. Metabotropic glutamate receptors modulate serotonin release in the rat periaqueductal gray matter
34. Monoamine oxidase inhibitors reduce conditioned fear stress-induced freezing behavior in rats
35. 1 muscarinic receptors in brain
36. Potential treatment paradigms for anxiety disorders
37. Pretreatment with diazepam suppresses the reduction in defensive freezing behavior induced by fluboxamine in the conditioned fear stress paradigm in mice
38. Biochemical and behavioral anxiolytic-like effects of R(+)HA-966 at the level of the ventral tegmental area in rats
39. Effects of diazepam, meprobamate, chlorpromazine and apomorphine on a quickly learned conditioned suppression in mice
40. Serotonergic mechanisms involved in the attentional and vigilance task performance of rats and the palliative action of aniracetam
41. Activation of the reticulothalamic cholinergic pathway by the major metabolites of aniracetam
42. Antidepressant-like effects of aniracetam in aged rats and its mode of action
43. Scopolamine model of delirium in rats and reversal of the performance impairment by aniracetam
44. Apomorphine-induced hypo-attention in rats and reversal of the choice performance impairment by aniracetam
45. Impulsivity and AMPA receptors: Aniracetam ameliorates impulsive behavior induced by a blockade of AMPA receptors in rats
46. Site-specific activation of dopamine and serotonin transmission by aniracetam in the mesocorticolimbic pathway of rats
47. Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area
48. Brain mechanisms of social anxiety disorder
49. Serotonergic modulation of social interactions in isolated male mice
50. Clinical usefulness of aniracetam for psychiatric symptoms in patients with cerebrovascular disorders: Placebo controlled double-blind trial
51. Antidepressant treatment of posttraumatic stress disorder
52. A study of nootropic drugs for anti-anxiety action
53. Effects of systemic nicotine on serotonin release in rat brain
54. Effects of scopolamine and its quaternary analogue in the murine elevated plus-maze test of anxiety
55. Group II metabotropic glutamate receptors are a common target of N-anisoyl-GABA and 1S, 3R-ACPD in enhancing ACh release in the prefrontal cortex of freely moving SHRSP
56. A PHA-L analysis of ascending projections of the dorsal raphe nucleus in the rat
57. Cholinergic modulation of a decrement in social investigation following repeated contacts between mice
58. Regulation of nucleus accumbens dopamine release by the dorsal raphe nucleus in the rat